Is UNII-1Y740ILL1Z Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-1Y740ILL1Z? Is UNII-1Y740ILL1Z safe for nursing mother and child? Does UNII-1Y740ILL1Z extracts into breast milk? Does UNII-1Y740ILL1Z has any long term or short term side effects on infants? Can UNII-1Y740ILL1Z influence milk supply or can UNII-1Y740ILL1Z decrease milk supply in lactating mothers?

Information from one maternal-infant pair with UNII-1Y740ILL1Z and lumacaftor indicates that maternal UNII-1Y740ILL1Z therapy produce low levels in milk. The breastfed infant had transient elevations in bilirubin and liver enzymes during maternal therapy that could not definitively be attributed to the drugs in breastmilk. Effect of small amounts of UNII-1Y740ILL1Z in infants and small children is unknown. Until more data are available, monitoring of infant bilirubin and liver enzymes is recommended during breastfeeding with maternal lumacaftor and UNII-1Y740ILL1Z therapy.

A woman with cystic fibrosis was treated with lumacaftor and UNII-1Y740ILL1Z during pregnancy and postpartum. Her infant was fully breastfed until day 29 postpartum when elevated direct and indirect bilirubin, aspartate aminotransferase (AST), and alkaline phosphatase were found to be elevated. All values had been normal on days 1 and 14. The fraction of breastmilk the infant received was reduced to 25% and all values were normal on day 37. The fraction of breastfeeding was increased to 50% and then to 100%. On day 135, the infant's direct bilirubin was elevated during concurrent maternal levofloxacin and trimethoprim-sulfamethoxazole therapy. The fraction of breastfeeding was decreased to 75% and the direct bilirubin was normal on day 154. The authors noted that the abnormal test results could not definitively be attributed to lumacaftor and UNII-1Y740ILL1Z therapy.[1]